Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors. Read More
Scribe Therapeutics unveils ELXR technology breakthrough at Keystone Symposia 2025
Scribe Therapeutics has presented new data on its Epigenetic Long-Term X-Repressor (ELXR) technology at the 2025 Keystone Symposia on Precision Genome Engineering, showcasing a significant ... Read More
Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy
Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market. The company reaffirmed its 2025 financial guidance, ... Read More
Novo Nordisk’s Amycretin outshines rivals in weight-loss drug trials
Novo Nordisk has achieved a critical milestone in the fight against obesity, reporting highly promising results from an early-stage clinical trial of its weight-loss drug, ... Read More
Schrödinger stock skyrockets as Novartis invests billions in new partnership
In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement with Novartis AG, potentially valued at up ... Read More
Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue ... Read More
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising ... Read More
UK approves Lilly’s Alzheimer’s drug but labels it ‘too expensive’ for NHS use
The UK has approved Eli Lilly's new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and ... Read More
New hope for eczema sufferers as FDA approves Eli Lilly’s EBGLYSS
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its new biologic treatment, EBGLYSS (lebrikizumab-lbkz), for moderate-to-severe ... Read More
Eli Lilly to expand manufacturing with $1bn investment in Ireland to boost Alzheimer’s drug production
Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production ... Read More